D4 Bioventures in Asia Pacific
Australian expertise. Regional experience. Broader opportunities.
D4 Bioventures’ reach extends beyond Australia. We bring life science expertise, commercial experience and established relationships across Hong Kong, Singapore and Southeast Asia to help founders, research institutions and businesses explore regional opportunities.
Across drugs, devices, diagnostics and digital health, we help teams evaluate technologies, build ventures, sharpen commercial strategy and prepare for discussions with potential business partners. Our team’s experience connects Australian innovation with Asian markets and supports international companies seeking opportunities in Australia and the wider region.
Experience built across the region
Peter Golovsky brings more than 25 years of global financial services experience, including over a decade based in Asia. His career encompasses senior leadership in private wealth and family office services, following roles at Macquarie, Westpac and Andersen. He has worked closely with families, family offices and their operating businesses across Hong Kong, Singapore and Southeast Asia. His work extends to Indonesia and Thailand, bringing D4 insight into business relationships and commercial opportunities across these markets.
David Barda brings direct experience of Singapore’s biomedical innovation ecosystem. Before joining the Garvan Institute of Medical Research, he led a team commercialising medical technologies at A*STAR, Singapore’s national science and technology agency, contributing to the creation of more than 15 life science ventures.
Dr Steven Suchting previously led the Life Sciences Division of the National University of Singapore’s Industry Liaison Office. His experience in technology transfer, venture development and commercial partnerships adds further depth to D4’s understanding of how research becomes a viable business.
Together, these backgrounds give D4 practical insight into the research institutions, commercial networks and business environments that shape opportunities across Asia Pacific.
A track record beyond Australia
Our team’s APAC client experience includes Life Biosciences, Minerva Biotechnologies, Antabio and Porcine Therapeutics.
These relationships sit alongside D4’s work with Australian research institutions and emerging companies, reflecting a regional outlook that brings scientific understanding and commercial judgement to opportunities across borders.
Supporting your regional ambitions
Whether you are an Australian company exploring Asia or an international business seeking Australian expertise, D4 can help you:
-
Assess commercial opportunities and prioritise markets.
-
Develop a clear business model and commercialisation strategy.
-
Build ventures around promising research and technology.
-
Prepare business plans, development roadmaps and company materials.
-
Identify potential research collaborators, industry partners and commercial relationships.
Each engagement is scoped to the client’s needs and the legal and regulatory requirements of the relevant jurisdictions.
Regulatory information
D4 Bioventures does not hold financial services licences in Hong Kong or Singapore and does not offer services in those jurisdictions that require such licences. Any activity requiring local licensing or authorisation must be undertaken by an appropriately authorised provider.
In Australia, SWG Capital Pty Ltd (ABN 37 135 455 864) is a Corporate Authorised Representative (CAR No. 001296052) of FB Corp Pty Ltd (ABN 16 675 876 490, AFSL No. 557810). Any Australian regulated financial services are provided only within the scope of that authorisation.
This page provides general information about D4’s experience and capabilities. It does not constitute financial product advice, an offer of securities or a solicitation to invest.